Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
Want to see GUTS full AI Analyst Report?
GUTS Stock Chart & Stats
$0.57
-$0.12(-5.94%)
At close: 4:00 PM EST
$0.57
-$0.12(-5.94%)
Day’s Range― - ―
52-Week Range$0.38 - $2.45
Previous Close$1.96
Volume269.01K
Average Volume (3M)2.30M
Market Cap
$136.17M
Enterprise Value$59.01M
Total Cash (Recent Filing)$63.17M
Total Debt (Recent Filing)$60.82M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Aug 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding158,648,960
10 Day Avg. Volume2,233,019
30 Day Avg. Volume2,300,071
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)17.64
Price to Sales (P/S)0.00
P/FCF Ratio-1.84
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$5.00Price Target Upside777.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory & Reimbursement MomentumRegulatory designations and favorable de novo feedback materially lower approval uncertainty and can accelerate payer engagement. Breakthrough status and RAPID pathway alignment improve the odds of quicker Medicare coverage and hospital adoption, supporting a more durable commercial pathway if clinical readouts hold.
Pivotal Trial ExecutionA large, fully randomized, sham‑controlled pivotal with high retention and consistent blinded safety reduces execution and data‑integrity risk. Reliable trial conduct and robust endpoints increase the likelihood that positive top‑line results will translate into regulatory decisions and real‑world clinician acceptance.
Pipeline Diversification Via RejuvaAdvancing RJVA‑001 to first‑in‑human development creates a second clinical program beyond Revita, diversifying long‑term value drivers. A distinct gene‑therapy approach targeting T2D complements the endoscopic platform and, if successful, could expand addressable markets and reduce dependence on a single product outcome.
Bears Say
Pre-revenue With Large LossesSustained net losses and heavy cash burn reflect an early‑stage biotech still investing in trials, leaving no operational cash generation. Continued negative cash flow necessitates external financing to fund pivotal commercialization, increasing the likelihood of dilution and constraining strategic flexibility over the medium term.
Limited Cash RunwayA runway only into early 2027 creates a hard financing clock tied to clinical timelines. Any delays or need for additional studies could force near‑term capital raises under pressure, risking dilution or constrained program execution and weakening the company's ability to pursue commercialization activities before approval.
Elevated Leverage Vs EquityMaterial debt relative to a small equity base increases refinancing and interest‑coverage risk for a loss‑making company. Elevated leverage limits flexibility to fund trials or commercial scale‑up, raises default/refinancing concerns if markets tighten, and reduces optionality for strategic partnerships or acquisitions.
Fractyl Health, Inc. News
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $0.38 and its highest was $2.44 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $136.17M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 58 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on May 12, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.22.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 158,648,960 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 29.155%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fractyl Health, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (777.19% Upside)
$5.00 (777.19% Upside)
Blogger Sentiment
Bullish
GUTS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $108.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.07%
12-Months-Change
Fundamentals
Return on Equity
-4573.89%
Trailing 12-Months
Asset Growth
19.68%
Trailing 12-Months
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc. is a biopharmaceutical firm dedicated to advancing treatments for type 2 diabetes (T2D) and obesity. Among its offerings is the Revita DMR System (Revita), an outpatient procedure engineered to provide lasting modification of duodenal dysfunction. This condition often arises from diets high in fat and sugar, playing a role in the onset of T2D and obesity in individuals. Fractyl Health is also pioneering Rejuva, an innovative gene therapy platform utilizing a viral delivery system directly to the pancreas. Rejuva's objective is to achieve long-term remission from T2D and obesity by fundamentally altering metabolic hormone function within patients' pancreatic islet cells. Incorporated in 2010, the company, formerly known as Fractyl Laboratories Inc., officially became Fractyl Health, Inc. on June 9, 2021. Its operations are headquartered in Lexington, Massachusetts.
GUTS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical execution, external validation, regulatory and reimbursement progress, and a clear catalyst timeline — all supportive of the company's strategic thesis. Financially, the company has reduced operating spend and improved adjusted EBITDA, but remains cash-limited with a runway into early 2027 and continues to report negative adjusted profitability. Several regulatory and operational uncertainties remain (RAPID implementation, full de novo approval, U.S. regulatory engagement for Rejuva) and the near-term plan is contingent on multiple upcoming clinical readouts. Overall, clinical and regulatory momentum and cost discipline are material positives, but the constrained cash runway and remaining execution/regulatory risks temper the outlook.View all GUTS earnings summariesGUTS Stock 12 Month Forecast
Average Price Target
$5.00
▲(777.19% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
―
Innate Pharma
―
Ownership Overview
6.64% Insiders
4.29% Mutual Funds
36.26% Other Institutional Investors
49.20% Public Companies and Individual Investors
Options Prices
Currently, No data available
---